Ocera Therapeutics, Inc. (NASDAQ:OCRX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.

According to Zacks, “Ocera Therapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of proprietary compounds to treat acute and chronic orphan liver diseases. Ocera Therapeutics, Inc., formerly known as Tranzyme, Inc., is based in San Diego, California. “

Ocera Therapeutics (NASDAQ OCRX) opened at 1.11 on Wednesday. The stock’s market capitalization is $29.43 million. The company has a 50 day moving average of $1.02 and a 200-day moving average of $1.13. Ocera Therapeutics has a 52-week low of $0.52 and a 52-week high of $3.07.

Ocera Therapeutics (NASDAQ:OCRX) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.01. Equities research analysts anticipate that Ocera Therapeutics will post ($1.20) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/10/04/ocera-therapeutics-inc-ocrx-downgraded-to-hold-at-zacks-investment-research.html.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Hikari Power Ltd boosted its stake in Ocera Therapeutics by 50.6% during the 2nd quarter. Hikari Power Ltd now owns 376,596 shares of the biopharmaceutical company’s stock valued at $437,000 after acquiring an additional 126,596 shares during the last quarter. Virtu KCG Holdings LLC grew its holdings in Ocera Therapeutics by 194.6% during the 2nd quarter. Virtu KCG Holdings LLC now owns 213,531 shares of the biopharmaceutical company’s stock worth $248,000 after acquiring an additional 141,040 shares in the last quarter. Finally, Perceptive Advisors LLC acquired a new position in Ocera Therapeutics during the 1st quarter worth $2,817,000. 20.25% of the stock is currently owned by hedge funds and other institutional investors.

Ocera Therapeutics Company Profile

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

Analyst Recommendations for Ocera Therapeutics (NASDAQ:OCRX)

Receive News & Stock Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related stocks with our FREE daily email newsletter.